X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DIVIS LABORATORIES NATCO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 16.0 32.5 49.2% View Chart
P/BV x 17.2 5.8 296.3% View Chart
Dividend Yield % 0.7 0.9 77.9%  

Financials

 NATCO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
DIVIS LABORATORIES
Mar-17
NATCO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8771,222 71.8%   
Low Rs424784 54.0%   
Sales per share (Unadj.) Rs223.4153.1 145.9%  
Earnings per share (Unadj.) Rs31.139.9 77.8%  
Cash flow per share (Unadj.) Rs40.344.6 90.3%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %0.81.0 77.1%  
Book value per share (Unadj.) Rs219.5201.8 108.8%  
Shares outstanding (eoy) m33.07265.47 12.5%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.96.6 44.4%   
Avg P/E ratio x20.925.1 83.4%  
P/CF ratio (eoy) x16.122.5 71.8%  
Price / Book Value ratio x3.05.0 59.6%  
Dividend payout %16.125.0 64.3%   
Avg Mkt Cap Rs m21,504266,266 8.1%   
No. of employees `000NA9.7 0.0%   
Total wages/salary Rs m1,1284,687 24.1%   
Avg. sales/employee Rs ThNM4,175.0-  
Avg. wages/employee Rs ThNM481.5-  
Avg. net profit/employee Rs ThNM1,089.3-  
INCOME DATA
Net Sales Rs m7,38940,643 18.2%  
Other income Rs m167749 22.3%   
Total revenues Rs m7,55641,392 18.3%   
Gross profit Rs m1,79314,460 12.4%  
Depreciation Rs m3041,233 24.7%   
Interest Rs m36623 1,620.4%   
Profit before tax Rs m1,29013,953 9.2%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3093,349 9.2%   
Profit after tax Rs m1,02710,604 9.7%  
Gross profit margin %24.335.6 68.2%  
Effective tax rate %23.924.0 99.7%   
Net profit margin %13.926.1 53.3%  
BALANCE SHEET DATA
Current assets Rs m3,68140,105 9.2%   
Current liabilities Rs m3,1236,595 47.4%   
Net working cap to sales %7.682.5 9.2%  
Current ratio x1.26.1 19.4%  
Inventory Days Days89119 75.5%  
Debtors Days Days5981 72.7%  
Net fixed assets Rs m7,68519,995 38.4%   
Share capital Rs m331531 62.3%   
"Free" reserves Rs m6,67053,043 12.6%   
Net worth Rs m7,25953,574 13.5%   
Long term debt Rs m9550-   
Total assets Rs m11,95761,585 19.4%  
Interest coverage x4.5618.4 0.7%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.7 93.6%   
Return on assets %11.717.3 67.5%  
Return on equity %14.219.8 71.5%  
Return on capital %20.726.1 79.4%  
Exports to sales %39.40-   
Imports to sales %5.725.2 22.6%   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m42110,259 4.1%   
Fx inflow Rs m3,44535,384 9.7%   
Fx outflow Rs m70310,399 6.8%   
Net fx Rs m2,74324,985 11.0%   
CASH FLOW
From Operations Rs m1,44011,493 12.5%  
From Investments Rs m-1,089-11,372 9.6%  
From Financial Activity Rs m-353-93 378.8%  
Net Cashflow Rs m-128 -5.2%  

Share Holding

Indian Promoters % 52.0 52.0 100.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.8 66.4%  
FIIs % 16.6 19.0 87.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.2 151.2%  
Shareholders   25,395 31,796 79.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - SUN PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS